评论：COVID-19肺部疾病中的抗纤维化药物：让我们保持专注。 - Suppr

Suppr

超能文献

Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

作者信息

Seifirad Soroush, Alquran Lance

机构信息

Department of Internal Medicine, Hackensack Meridian Health Mountainside Medical Center, Montclair, NJ, United States.

出版信息

Front Med (Lausanne). 2021 Jan 11;7:625440. doi: 10.3389/fmed.2020.625440. eCollection 2020.

DOI:10.3389/fmed.2020.625440

PMID:33585519

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7874198/

Abstract

摘要

相似文献

Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

Front Med (Lausanne). 2021 Jan 11;7:625440. doi: 10.3389/fmed.2020.625440. eCollection 2020.

Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

Front Med (Lausanne). 2021 Mar 11;7:604640. doi: 10.3389/fmed.2020.604640. eCollection 2020.

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

Front Med (Lausanne). 2020 Sep 9;7:539. doi: 10.3389/fmed.2020.00539. eCollection 2020.

New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis.

Adv Respir Med. 2021;89(1):84-85. doi: 10.5603/ARM.a2020.0177. Epub 2021 Jan 20.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Front Pharmacol. 2018 Dec 17;9:1480. doi: 10.3389/fphar.2018.01480. eCollection 2018.

Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):220-3. doi: 10.1016/j.bmcl.2013.11.038. Epub 2013 Nov 25.

Combination Therapy With Polydeoxyribonucleotide and Pirfenidone Alleviates Symptoms of Acute Respiratory Distress Syndrome in Human Lung Epithelial A549 Cells.

Int Neurourol J. 2020 May;24(Suppl 1):S56-64. doi: 10.5213/inj.2040152.076. Epub 2020 May 31.

Novel management strategies for idiopathic pulmonary fibrosis.

Expert Rev Respir Med. 2018 Oct;12(10):831-842. doi: 10.1080/17476348.2018.1513332. Epub 2018 Aug 30.

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives.

Ther Clin Risk Manag. 2019 Jan 3;15:73-81. doi: 10.2147/TCRM.S160248. eCollection 2019.

引用本文的文献

Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.

Pneumonia (Nathan). 2021 Dec 6;13(1):14. doi: 10.1186/s41479-021-00092-9.

The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy.

Antioxidants (Basel). 2021 Jul 20;10(7):1152. doi: 10.3390/antiox10071152.

本文引用的文献

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

Front Med (Lausanne). 2020 Sep 9;7:539. doi: 10.3389/fmed.2020.00539. eCollection 2020.

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.

PLoS One. 2020 Oct 2;15(10):e0240149. doi: 10.1371/journal.pone.0240149. eCollection 2020.

COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis.

Front Med (Lausanne). 2020 Jul 21;7:459. doi: 10.3389/fmed.2020.00459. eCollection 2020.

Atypical Presentation of COVID-19 Leading to ARDS.

Case Rep Infect Dis. 2020 Jul 2;2020:1070249. doi: 10.1155/2020/1070249. eCollection 2020.

Pirfenidone: A novel hypothetical treatment for COVID-19.

Med Hypotheses. 2020 Nov;144:110005. doi: 10.1016/j.mehy.2020.110005. Epub 2020 Jun 17.

Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series.

Front Med (Lausanne). 2020 May 15;7:231. doi: 10.3389/fmed.2020.00231. eCollection 2020.

CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19).

J Med Virol. 2020 Oct;92(10):1721-1723. doi: 10.1002/jmv.25804. Epub 2020 Apr 17.

Pirfenidone attenuates homocysteine‑induced apoptosis by regulating the connexin 43 pathway in H9C2 cells.

Int J Mol Med. 2020 Apr;45(4):1081-1090. doi: 10.3892/ijmm.2020.4497. Epub 2020 Feb 13.

Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine.

EPMA J. 2019 Jul 31;10(3):195-209. doi: 10.1007/s13167-019-00176-z. eCollection 2019 Sep.

Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.

Radiat Res. 2018 Oct;190(4):396-403. doi: 10.1667/RR15017.1. Epub 2018 Jul 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验